Method for treatment of insulin resistance in obesity and diabetes
AssigneesEleanor Roosevelt Institute, Olkahoma Medical Research Foundation
InventorsMiles B. Brennan, Ute Bochgeschwender
Life of this patent
Estimating the term…
Abstract
Disclosed is a method to identify compounds useful for reducing insulin resistance in a patient, and particularly a patient that has insulin resistance associated with obesity and/or type II diabetes. Also disclosed is a method of reducing insulin resistance in a patient by administering a compound identified using the method of the invention, and particularly, by administering an antagonist of melanocortin stimulating hormone (MSH) biological activity.
Claims20
A method to identify compounds useful in regulating insulin resistance in obesity and type II diabetes, comprising:
- a. administering a compound having melanocyte stimulating hormone (MSH) biological activity to a genetically modified non-human animal comprising a genetic modification within two alleles of its Pomc locus, wherein said genetic modification results in an absence of proopiomelanocortin (Pomc) peptide activity in said animal, and wherein administration of said compound having MSH activity induces insulin resistance in said animal;
- b. administering a compound to be evaluated to said non-human animal model;
- and,
- c. selecting compounds from (b) that decrease the insulin resistance in said non-human animal as compared to in the absence of said compound of (b).
A method to decrease insulin resistance in a mammal, comprising administering to said mammal that has insulin resistance a therapeutic composition comprising an antagonist of melanocortin stimulating hormone (MSH) biological activity, wherein said antagonist decreases insulin resistance in said mammal.
A method to treat diabetes associated with insulin resistance in a mammal, comprising administering to said mammal that has insulin resistance and diabetes a therapeutic composition comprising an antagonist of melanocortin stimulating hormone (MSH) biological activity, wherein said antagonist decreases insulin resistance in said mammal.
Dependencies are inferred from the claim text.